Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma-Reference-Cited by-同舟云学术

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Published:2015-11-05 Issue:19 Volume:373 Page:1803-1813
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Motzer Robert J.,Escudier Bernard,McDermott David F.,George Saby,Hammers Hans J.,Srinivas Sandhya,Tykodi Scott S.,Sosman Jeffrey A.,Procopio Giuseppe,Plimack Elizabeth R.,Castellano Daniel,Choueiri Toni K.,Gurney Howard,Donskov Frede,Bono Petri,Wagstaff John,Gauler Thomas C.,Ueda Takeshi,Tomita Yoshihiko,Schutz Fabio A.,Kollmannsberger Christian,Larkin James,Ravaud Alain,Simon Jason S.,Xu Li-An,Waxman Ian M.,Sharma Padmanee

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1510665

Cited by 4894 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research Progress of PD 1/PD L1 Inhibitors in the Treatment of Urological Tumors;Current Cancer Drug Targets;2024-11

2. Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer;Urologic Oncology: Seminars and Original Investigations;2024-11

3. Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors;Cancer Epidemiology;2024-10

4. Design and evaluation of novel inhibitors for the treatment of clear cell renal cell carcinoma;Bioorganic Chemistry;2024-10

5. Toxicity profiles of immune checkpoint inhibitors in nervous system cancer: a comprehensive disproportionality analysis using FDA adverse event reporting system;Clinical and Experimental Medicine;2024-09-09